儿童及青少年白癜风局部治疗专家建议
美国专家基于文献综述与共识流程,制定儿童、青少年及年轻成人白癜风诊断与局部治疗的推荐。推荐局部钙调神经磷酸酶抑制剂每日两次、限时使用局部糖皮质激素、局部ruxolitinib 1.5%乳膏超说明书用于12岁以下非节段性白癜风。
要点
- 局部钙调神经磷酸酶抑制剂每日两次为一线治疗。
- 局部糖皮质激素需限时使用以降低萎缩风险。
- 局部ruxolitinib 1.5%乳膏可超说明书用于12岁以下非节段性白癜风。
核心结论
- 证据支持局部钙调神经磷酸酶抑制剂、局部糖皮质激素和局部JAK抑制剂是儿童、青少年及年轻成人白癜风的有效治疗。
- 选择具体药物需基于部位、体表面积和年龄等因素决定。
研究设计与样本
- 通过文献综述和共识流程制定儿童白癜风推荐,文献由图书馆员检索,纳入英文、含原始数据(含荟萃分析)和儿童特异性数据、分析6例及以上患者的文章。
- 纳入文章按推荐强度分类法和牛津循证医学中心证据等级分级,2022年5月9日视频会议审查研究问题,一个月后参与者用5点李克特量表在线调查对声明的同意程度。
主要发现
- 纳入局部糖皮质激素和/或局部钙调神经磷酸酶抑制剂文章50篇,局部JAK抑制剂5篇,假性过氧化氢酶2篇,微晶磨削2篇。
关键数值与推荐
- 局部钙调神经磷酸酶抑制剂每日两次、局部糖皮质激素因萎缩风险需限时使用、局部ruxolitinib 1.5%乳膏超说明书用于12岁以下患者且限于非节段性白癜风,被确定为循证一线治疗。
- 推荐包括基于年龄的数据指导、最小治疗试验6个月或更长、长期治疗以预防复发、协调使用紫外线治疗来源的正面获益。
临床怎么用
- 临床可依据年龄、部位和体表面积选择局部钙调神经磷酸酶抑制剂、局部糖皮质激素或局部JAK抑制剂。
- 局部糖皮质激素应限时使用,局部ruxolitinib 1.5%乳膏可用于12岁以下非节段性白癜风(超说明书)。
- 治疗试验应持续至少6个月,并考虑长期治疗预防复发及协调紫外线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed. OBJECTIVE: To develop evidence- and consensus-based expert recommendations on the diagnosis and treatment of vitiligo in young patients. EVIDENCE REVIEW: A process was developed to produce consensus recommendations addressing questions regarding pediatric vitiligo. A librarian-conducted literature review was performed using articles that met the inclusion criteria: published in English, containing primary data (including meta-analysis) and pediatric-specific data, and analysis of 6 or more patients. Included articles were graded by the Strength of Recommendation Taxonomy criteria and Oxford Centre for Evidence-based Medicine's Levels of Evidence and Grades of Recommendation. Research questions were reviewed on May 9, 2022, through a video conference. One month after the conference, participants participated in an online survey documenting their level of agreement with the generated statements, using a 5-point Likert scale. FINDINGS: Articles on topical corticosteroids and/or topical calcineurin inhibitors (n = 50), topical Janus kinase inhibitors (n = 5), pseudocatalase (n = 2), and microdermabrasion (n = 2) met inclusion criteria. Forty-two recommendations were made on the diagnosis of vitiligo and optimal topical therapeutics, with 33 recommendations obtaining a 70% or greater composite agreement and strong agreement. Topical calcineurin inhibitors twice daily, topical corticosteroids with time limitation due to atrophy risk, and topical ruxolitinib, 1.5%, cream-used off-label for patients younger than 12 years and limited to nonsegmental vitiligo-were identified as evidence-based first-line therapies in the management of pediatric and adolescent patients, with specific guidance on age-based data, minimum therapeutic trial of 6 months or greater, prolonged therapy to prevent recurrence, and the positive benefit of coordinated use of UV therapeutic sources. CONCLUSIONS AND RELEVANCE: Evidence supports the use of topical calcineurin inhibitors, topical corticosteroids, and topical Janus kinase inhibitors as effective therapeutics for vitiligo in pediatric, adolescent, and young adult patients, with specific decisions on choice of agent based on factors such as site location, body surface area, and age.
引用
- Renert-Yuval Y, Ezzedine K, Grimes P, et al. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. JAMA Dermatol. 2024. PMID: 38477910. doi:10.1001/jamadermatol.2024.0021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。